Mark Stamm, MD
Ophthalmology · Lewes, DENPI 1922082387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 32.5% of the total. Reporting peaked in 2019 at $590 and has fallen 87.1% since, to $76 in 2024.
Across 68 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$665
- Novo Nordisk$250
- Sun Pharmaceutical Industries Inc.$231
- Alcon$224
- Novartis$172
- Mallinckrodt Hospital Products Inc.$114
- plus $389 from 14 others
What the payments were for
- Speaking & faculty fees$472%
- Food & beverage$1,85891%
- Education$1407%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $665 |
| Novo Nordisk | 4 | $250 |
| Sun Pharmaceutical Industries Inc. | 7 | $231 |
| Alcon | 7 | $224 |
| Novartis | 9 | $172 |
| Mallinckrodt Hospital Products Inc. | 2 | $114 |
| Eyepoint US, Inc. | 4 | $80 |
| Harrow Eye, LLC | 2 | $51 |
| Notal Vision, Inc. | 1 | $47 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Omeros Corporation | 1 | $21 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,044 in reported general payments places this provider in the 70th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 19 | $33,145 |
| LumiganBimatoprost | 35 | $22,994 |
| XiidraLifitegrast | 16 | $17,364 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,775 |
| RhopressaNetarsudil Mesylate | 15 | $5,293 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,036 |
| Bromfenac Sodium | 16 | $2,462 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,308 |
| Prednisolone Acetate | 57 | $2,081 |
| Travoprost | 14 | $1,993 |
| Latanoprost | 208 | $1,814 |
| Gatifloxacin | 41 | $1,777 |
| Timolol Maleate | 58 | $1,564 |
| Ketorolac Tromethamine | 27 | $1,040 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $665 | $60,17565 claims |
| Bausch & Lomb Americas Inc.Xiidra | $21 | $17,36416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Lewes
- Rodolfo RiosLewes$230
- David CreechDover$22K
- Bryan SeiffDover$9K
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- David LuDover$5K
- Richard SherryWilmington$5K
- Karen RudoMilford$5K
- Scott FudembergRehoboth Beach$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.